Beleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the ...
Isomorphic Labs has raised a $5 billion series C round, marking the second time in six months that the AI drug development ...
A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in overall funding ...
Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia (AML) has passed a phase 3 test with a more than nine-month ...
CG now plans to complete that expanded FDA submission by the end of 2027’s first quarter. Meanwhile, in intermediate ...
Eli Lilly has added another myelofibrosis (MF) play to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech ...
TrimTech Therapeutics has been tapped by Biogen in a $411 million biobucks collaboration to develop protein degraders for ...
Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to ...
Flagship Pioneering has picked London as the site of the venture capital powerhouse’s first company-creation unit outside of ...
A phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the ...
Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to ...
While Kyverna awaits an FDA decision on whether to grant the first-ever approval for an autoimmune CAR-T therapy, the biotech ...